MS Clinical Trial Unit
Dr Gavin Giovannoni
In partnership with the NHNN, this Unit is responsible for the performing clinical trials in subjects with MS.
Currently, several phase II and phase III studies are evaluating a spectrum of novel disease modifying therapies for MS (e.g. natalizumab, an anti-adhesion molecule therapy). In partnership with the NMR Research Unit, the MS Clinical Trials Unit is now in a position to assist and perform investigator-led studies; this important function helps in the translation of other MS-related basic research currently been undertaken at the ION.